But that is changing. The number of new prescriptions written for biosimilar versions of Humira soared to 36% from just 5% ...

CVS is getting into the business of making copycat biologic drugs, known as biosimilars, to profit directly from blockbusters ...

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Hello, and welcome to today's CVS Health Q1 2024 earnings conference call. My name is Jordan, and I'll be coordinating your ...

In the three weeks leading up to today’s earnings call, AbbVie was navigating a major formulary change at CVS Health’s pharmacy benefit manager, which replaced Humira with a biosimilar on April 1.

Script Intelligence , can save CVS Caremark pharmacy benefit management (PBM) members between $120-$130 per prescription fill. The company found that, when provided with access to member-specific ...

Pharmaceutical giant AbbVie managed to hang on to most of the immunosuppressive drug market in the first year its multiuse drug Humira faced biosimilar competition, but the tide appears to be ...

CVS Caremark is therefore granting preferential placement on its formulary to another branded inhaler, Pulmicort, in lieu of the authorized generic versions of Flovent. In other words, makers of ...

In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized ...

Bank of America Securities analyst Allen Lutz has maintained their bullish stance on CVS stock, giving a Buy rating on April 22. Allen Lutz ...

Evan Seigerman, an analyst from BMO Capital, assigned the Buy rating on AbbVie (ABBV – Research Report). The associated price target was ...